Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 12/20 | 0.58 |
| ▸ | ADH1C | P00326 | 9/20 | 0.58 |
| ▸ | ADH1B | P00325 | 5/20 | 0.58 |
| ▸ | ADH7 | P40394 | 2/20 | 0.58 |
| ▸ | ADH4 | P08319 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27343431 | 0.83 | ADH1B (0.46) | ADH1AADH1CADH1BADH7ADH4 | |
| SCHEMBL21386086 | 0.79 | ADH1B (0.32) | ADH1AADH1CADH1BADH7 | |
| SCHEMBL18502882 | 0.79 | ADH1B (0.32) | ADH1AADH1CADH1BADH7 | |
| SCHEMBL1781234 | 0.77 | ADH1A (0.64) | ADH1AADH1CADH1BADH7ADH4 | |
| SCHEMBL1766618 | 0.75 | ADH1B (0.62) | ADH1AADH1CADH1BADH7ADH4 | |
| SCHEMBL115509 | 0.75 | — | — | |
| SCHEMBL4917504 | 0.72 | — | — | |
| SCHEMBL24501969 | 0.71 | ADH1B (0.62) | ADH1AADH1CADH1BADH7ADH4 | |
| SCHEMBL22883812 | 0.71 | ADH1B (0.62) | ADH1AADH1CADH1BADH7ADH4 | |
| SCHEMBL22883564 | 0.71 | ADH1B (0.62) | ADH1AADH1CADH1BADH7ADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319019-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| EP-1833802-A2 | 1,2-DIPHENYL-IMIDAZOLE DERIVATIVES AND THEIR USE AS CB1 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006067428-A2 | 1, 2-DIPHENYL-IMIDAZOLE DERIVATIVES AND THEIR USE AS CB1 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319019-A1 | Therapeutic Agents | SDHA, GPR119, ABAT | ADH1A 253/4885ADH1C 403/4885ADH1B 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.